Navigation Links
Diakron Licenses Anticoagulant Drug Candidate from Merck & Co., Inc.
Date:8/13/2008

Orchid Pharma partners with Diakron

MORRIS PLAINS, N.J., Aug. 13 /PRNewswire/ -- Diakron Pharmaceuticals, Inc. announced today the signing of an exclusive license agreement for a novel investigational oral anticoagulant drug candidate discovered and developed through Phase I clinical trials by Merck & Co. Inc. Under the terms of the agreement, Diakron has the exclusive rights to develop, and, if approved, market and distribute the compound worldwide.

In a simultaneous transaction, Orchid Chemicals & Pharmaceuticals Ltd., the Chennai (India) based pharmaceutical major ("Orchid Pharma"), has signed an agreement to partner with Diakron as a significant shareholder and developer for the anticoagulant drug candidate. Orchid will be undertaking the next stages of development.

Announcing the successful conclusion of the agreements, Srirama Rao, PhD., a founder and the Chairman of Diakron said, "We are extremely pleased to be able to license this compound from Merck for further development and commercialization. We are also pleased that Orchid is partnering with us as a significant shareholder and developer of this compound, leveraging its world-class R&D infrastructure in India. This will allow Diakron to fast-track development of this unique anticoagulant product as its number one priority."

Commenting on the agreement, Dr. C.B. Rao, Deputy Managing Director of Orchid stated that partnering with Diakron for the development of this Merck compound is a significant development in Orchid's drug discovery journey. With its end-to-end drug discovery and drug development capability backed by US FDA and UK MHRA compliant manufacturing facilities, Orchid is well positioned to support the development of the compound all the way to successful commercialization, he observed.

"Despite recent advances there remains a significant unmet medical need for novel anticoagulant therapies," said Joseph Vacca, Executive Director of Medic
'/>"/>

SOURCE Diakron Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Poniard Pharmaceuticals Licenses Kinase Inhibitors From The Scripps Research Institute
2. Duska Therapeutics Licenses Portfolio of Heart Failure Drugs From Duke and Johns Hopkins
3. Duke Licenses ALPHADAS(R), Logos Technologies EDC System to Accelerate its Early Phase Clinical Trials
4. Genetics Determine Optimal Drug Dose of Common Anticoagulant
5. Nuvelo Initiates Phase 1B Clinical Trial of Anticoagulant NU172
6. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
7. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
8. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
9. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
10. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
11. Phase 2 Clinical Studies Initiated for a Novel Therapeutic Candidate Identified Through Pharmacopeia Collaboration

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2009)...30 Decision Resources, one of the ...ng on pharmaceutical and healthcare issues, foreca...ia will grow nine percent annually over the 2008 -... This growth will be driven mainly by increased go...of more-expensive therapies like pegylated interfe...
(Date:11/30/2009)...30 The U.S. Food and Dru... (duloxetine HCl) for the maintenance treatment of... Lilly and Company (NYSE: LLY ) announced today....a chronic illness, it is important that doctors an...ffective in both the acute and maintenance phase o...
(Date:11/30/2009)...30 Sanofi-aventis U.S. a...ng agreement with Intelliject, Inc. for a novel ep...t of allergic reactions (anaphylaxis) in North Ame...have this opportunity to offer this innovative del... risk of this life-threatening allergic reaction e...
Breaking Medicine Technology:Russia's Hepatitis C Virus Drug Market Will Grow Nine Percent Annually, Reaching $327 Million by 2013 2Russia's Hepatitis C Virus Drug Market Will Grow Nine Percent Annually, Reaching $327 Million by 2013 3FDA Approves Cymbalta(R) for Maintenance Treatment of Generalized Anxiety Disorder 2FDA Approves Cymbalta(R) for Maintenance Treatment of Generalized Anxiety Disorder 3FDA Approves Cymbalta(R) for Maintenance Treatment of Generalized Anxiety Disorder 4FDA Approves Cymbalta(R) for Maintenance Treatment of Generalized Anxiety Disorder 5Sanofi-aventis U.S. and Intelliject, Inc. Sign Licensing Agreement for Novel Epinephrine Auto Injector in North America 2Sanofi-aventis U.S. and Intelliject, Inc. Sign Licensing Agreement for Novel Epinephrine Auto Injector in North America 3DopeStats com Provides Statistics on Oxycodone Abused in Non Medical Purposes 61912 1DopeStats com Provides Statistics on Oxycodone Abused in Non Medical Purposes 61912 2Tis the Season to Eat and Eat More 21 61910 1Tis the Season to Eat and Eat More 21 61910 2New research shows versatility of amniotic fluid stem cells 61908 1New research shows versatility of amniotic fluid stem cells 61908 2
....Va., May 27 The Blanchette Rockefeller Neuroscie...tions, Inc. (Inverness, NYSE: IMA ) of Waltham, M... and health management, announced today that they ...alize a diagnostic test for Alzheimer,s disease fi...RNI test, once fully commercialized, could dramati...
...., May 26 Theranostics Health, Inc. (TH) is pleas...ical research study funded by the Susan G. Komen F...was the recipient of a Promise Grant, part of over...09 to further the development of new prevention an...san G. Komen for the Cure(R) is a nonprofit organi...
Other Medicine Technology:Blanchette Rockefeller Neurosciences Institute and Inverness Medical Innovations to Develop Commercial Test to Detect Early Alzheimer's Disease 2Blanchette Rockefeller Neurosciences Institute and Inverness Medical Innovations to Develop Commercial Test to Detect Early Alzheimer's Disease 3Blanchette Rockefeller Neurosciences Institute and Inverness Medical Innovations to Develop Commercial Test to Detect Early Alzheimer's Disease 4Theranostics Health Announces Involvement with Major Academic Medical Center in Study Funded by Susan G. Komen for the Cure(R) 2Theranostics Health Announces Involvement with Major Academic Medical Center in Study Funded by Susan G. Komen for the Cure(R) 3
(Date:11/30/2009)... , SILVER SPRING, Md., Nov. 30 /PRNewsw...se consumers a bronzed body year-round, but the ul...serious health risks. ,, (Logo: http://www.ne...Although some people think that a tan gives them a..." says Sharon Miller, M.S.E.E., a Food and Drug Ad...
(Date:11/30/2009)... , NASHVILLE, Tenn., Nov. 30 /PRNewswire...ng about gifts for the holidays. For a loved one w... family members and friends oftentimes struggle wi... Living , one of the leading providers of senior l...er,s and dementia care , offers these suggestions....
(Date:11/30/2009)... , PHILADELPHIA, ...- , - Exclusive Updates From Elsevier,s T...eform and ARRA Momentum , Elsevier, a wor...s well,as web-based and electronic health record (...nline resource center for American Recovery and Re...
(Date:11/30/2009)...he European Association of Urology (EAU) and Europ...ght against prostate cancer, have entered into an,... commitment to increase and improve,patient aware...., Professor Per-Anders Abrahamsson, Secretary-G...iliated partnership, Europa Uomo will gain access ...
(Date:11/30/2009)...CAGONovember 30, 2009A pet owner knows the enormou...cially in troubled times. Most pets are considered... companions. A growing body of research now docume...velopment, elderly care, mental illness, physical ...nd the rehabilitation of incarcerated youth and ad...
Breaking Medicine News(10 mins):Health News:Gift Ideas for Loved Ones with Alzheimer's/Dementia 2Health News:Elsevier Launches New Online ARRA Resource Center and Clinical Decision Support Blog 2Health News:Elsevier Launches New Online ARRA Resource Center and Clinical Decision Support Blog 3Health News:Elsevier Launches New Online ARRA Resource Center and Clinical Decision Support Blog 4Health News:The therapeutic benefits of the human-animal bond 2
...17-year old Irish girl who made headlines recently... by asserting her right to abort has got the nod ...the Court demanding that she be allowed to go to B...the foetus she is carrying suffers from anencephal...
...new vaccine aimed at preventing cervical cancer is...s of the human papillomavirus (HPV) responsible f...ionwide study of the vaccine will be published in ...ine marketed by Merck under the name Gardasil coul...
...combination of molecular-targeted therapy and horm...earch for those seeking an effective treatment fo... International Journal of Gynecological Cancer. ...tumors, says review author Dr. Siqing Fu, an assis...
...dia is home to over 76.6 million people over the a...e health ministry, the country has 76,622,321 per...cent of the elderly population, Uttar Pradesh tops... have 5.5 million senior citizens each. De...
... line with Ranbaxy Laboratories aggressive interna... Africa's Competition Commission has solidified th...mited ("Be-Tabs") by Ranbaxy Laboratories. (RNBV).... Ranbaxy Laboratories Limited, headquartered...
...alth authorities in the US are worried about yet a...quito-spread infection. Rudy Bueno, the Chi...id that the situation may worsen if people don't f...ellants or going out at night in short-sleeve shir...
Other Medicine News:Health News:Pregnant Irish Teenager Wins the Right to Abort 2Health News:Study Shows Continued Success for New HPV Vaccine Against Virus 2Health News:Ranbaxy Labs Extends Roots in South Africa 2Health News:Ranbaxy Labs Extends Roots in South Africa 3Health News:Health Authorities Fear West Nile Season Again in US 2
...ly 1990s, the "Reversed" shoulder prosthesis has b...success. More recently, an ever-growing number of ...on this prosthesis and the associated surgical tec...is the result of nearly fifteen years of clinical ...
AMINCO-Bowman Series 2 (AB2) Spectrofluorometer
SPEX Fluorolog-3
Gemini XPS Microplate Spectrofluorometer
Medicine Products: